{site-name}

  • Careers|
  • Sitemap|
  • Contact
  • WCBF Profile
  • Services & Products
  • Clinical Production
  • Quality Management System
  • Facility
  • Pact Project

Sitemap

Profile

  • WHY WAISMAN
  • Staff
  • Working with Waisman
  • Waisman Biomanufacturing Leadership
  • The UW Advantage
  • Connections
  • Upcoming Conferences / Meetings
  • Press Releases
  • Career Opportunities
  • Directions

Services and Products

  • WHY WAISMAN Services and Products
  • Process Development
  • cGMP Manufacturing
  • cGMP 3T3 Fibroblast Cells
  • cGMP rhFGF-basic (155 aa)

Clinical Production

  • WHY WAISMAN Clinical Production
  • GMP Plasmid DNA
  • GMP Protein Production
  • GMP Cell Therapeutics
  • GMP Viral Vectors / Vaccines
  • Aseptic Fill / Finish

Quality Management System

  • WHY WAISMAN Quality Management
  • Quality Assurance
  • Quality Control
  • Raw Materials / Product Storage
  • Standard Operating Procedures
  • Quality Control Procedures
  • Regulatory Links

Facility

  • WHY WAISMAN Facility
  • Microbial Processing Suite
  • Cell Processing Suites
  • Mammalian Processing Suite
  • Cell /  Viral Bank Storage
  • Facility Floor Plan

PACT Project

  • PACT Overview
  • PACT Management
  • PACT PI Highlight: Dr Abba Zubair
  • PACT Newsletter

Miscellaneous

  • Contact
Request Information

We have been extremely pleased with the ability of Waisman Biomanufacturing to produce GMP-grade cell therapy and viral products for our clinical trials.

— Mark Cantwell, Ph.D., Vice President of R&D, Memgen LLC

  • Home |
  • Profile |
  • Services & Products |
  • Clinical Production |
  • Quality Management System |
  • Facility |
  • PACT Project

© 2013 Waisman Biomanufacturing | Waisman Center home page | Site by Versa Studio